Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Pore-forming small molecules offer a promising way to tackle cystic fibrosis

In cystic fibrosis, ion-transport abnormalities cause problems in many organs. A small molecule that forms cell-membrane pores allowing ion transport shows therapeutic promise in human cells and a model of the disease.
  1. David N. Sheppard

    1. David N. Sheppard is in the School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Anthony P. Davis

    1. Anthony P. Davis is in the School of Chemistry, University of Bristol, Bristol BS8 4LN, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

In cystic fibrosis, abnormalities in the ion-channel protein CFTR cause problems in the transport of chloride (Cl−) and bicarbonate (HCO3−) ions in the epithelial cells that line the airways of lungs, resulting in a build-up of mucus in these airways. This hinders the normal process that removes mucus and the inhaled bacteria trapped in it, and the resulting airway blockage leads to persistent infections and inflammation, which destroy lung tissue1. Writing in Nature, Muraglia et al.2 demonstrate that a small molecule called amphotericin B, which can form an ion channel in the cellular membrane of airway cells, restores ion transport and antibacterial defences when tested in vitro in human cells from people with cystic fibrosis and in an in vivo animal model of the disease.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 567, 315-317 (2019)

doi: https://doi.org/10.1038/d41586-019-00781-y

References

  1. Ratjen, F. et al. Nature Rev. Dis. Primers 1, 15010 (2015).

    Article  PubMed  Google Scholar 

  2. Muraglia, K. A. et al. Nature 567, 405–408 (2019).

    Article  Google Scholar 

  3. Davies, J. C. et al. N. Engl. J. Med. 379, 1599–1611 (2018).

    Article  PubMed  Google Scholar 

  4. Keating, D. et al. N. Engl. J. Med. 379, 1612–1620 (2018).

    Article  PubMed  Google Scholar 

  5. Mall, M. A. & Galietta, L. J. V. J. Cystic Fibros. 14, 561–570 (2015).

    Article  Google Scholar 

  6. Shen, B., Li, X., Wang, F., Yao, X. & Yang, D. PLoS ONE 7, e34694 (2012).

    Article  PubMed  Google Scholar 

  7. Li, H. et al. Nature Chem. 8, 24–32 (2016).

    Article  PubMed  Google Scholar 

  8. Stoltz, D. A., Meyerholz, D. K. & Welsh, M. J. N. Engl. J. Med. 372, 351–362 (2015).

    Article  PubMed  Google Scholar 

  9. Quinton, P. M. Am. J. Physiol. Cell Physiol. 299, C1222–C1233 (2010).

    Article  PubMed  Google Scholar 

  10. Anderson, T. M. et al. Nature Chem. Biol. 10, 400–406 (2014).

    Article  PubMed  Google Scholar 

  11. Cioffi, A. G., Hou, J., Grillo, A. S., Diaz, K. A. & Burke, M. D. J. Am. Chem. Soc. 137, 10096–10099 (2015).

    Article  PubMed  Google Scholar 

  12. Grillo, A. S. et al. Science 356, 608–616 (2017).

    Article  PubMed  Google Scholar 

  13. Diamond, J. M. Nature 300, 683–685 (1982).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

D.N.S. is the recipient of a Vertex Innovation Award funded by Vertex Pharmaceuticals. The awards are administered by Chameleon, a medical communications company. Vertex Innovation Awards are reviewed by a grant-awarding panel, which selects reviewers to assess the applications and makes a final decision based on the comments of peer reviewers. Members of the grant-awarding panel and peer reviewers are academics and/or clinicians independent of Vertex Pharmaceuticals.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links